Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS(G12C) inhibitor-naïve Chinese patients with KRAS(G12C)-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies
IBI351（富泽拉西布）单药治疗KRAS(G12C)突变型转移性结直肠癌且既往未接受过KRAS(G12C)抑制剂治疗的中国患者的疗效和安全性：两项研究I期部分的汇总分析
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02315-7
Yuan, Ying; Deng, Yanhong; Jin, Yongdong; Guo, Zengqing; Pan, Yueyin; Wang, Cunji; Wang, Zhiwu; Hu, Yi; Hua, Dong; Meng, Xiangjiao; Zhang, Zhiye; Zhao, Mingfang; Dong, Xiaorong; Huang, Dingzhi; Li, Xiaoyan; Liu, Lian; Sun, Meili; Wang, Huijuan; Wang, Xiuwen; Yang, Nong; Zhang, Mingjun; Hu, Sheng; Wu, Dongde; Huang, Jingjing; Zhang, Sujie; Huang, Mengna; Ding, Kefeng
